Herbal medicine as a source of DPP-4 inhibitor for the treatment of Type 2 Diabetes

Article Sidebar

Pdf
Published: Dec 31, 2023
DOI: https://doi.org/10.53555/jrtdd.v6i10s(2).2948
Keywords:
Dipeptidyl peptidase-4 Type 2 diabetes glucagon-like peptide-1 (GLP-1) gastric inhibitory peptide (GIP) pancreatic β-cells Ocimum sanctum leaves Momordica charantia fruits etc

Main Article Content

Kuldip Kumar Savita
Raghuveer Irchhiaya
Roopam Kushwaha

Abstract

Insulin resistance and poor secretion lead to the metabolic condition known as type 2 diabetes. One of the protein enzymes involved in the control of blood glucose levels is dipeptidyl peptidase-4 (DPP-4), which is also known as adenosine deaminase complexing protein 2 (CD26) or glucagon like peptide -1 (GLP-1).While synthetic DPP-4 inhibitors are a powerful antidiabetic treatment for type 2 diabetes, they are still prohibitively costly and come with side effects. Herbal medicines are the rich source for diabetes treatment, in present investigation antidiabetic and DPP-4 inhibitory activity of aqueous and ethanolic extract of Ocimum sanctum leaves and Momordica charantia fruits were investigated on dose levels of 200,400 and 600 mg/kg/day for 28 days. In the study we revealed thatassessment of blood glucose levels in diabetic rats following treatment with different plant extracts we uncovered was truly remarkable. The Aqueous Extract of Ocimum sanctum leaves (OSAE), Ethanolic Extract of Ocimum sanctum leaves (OSEE), Aqueous Extract of Momordica charantia fruits (MCAE), and Ethanolic Extract of Momordica charantia fruits (MCEE) all exhibited distinct, yet potent, antidiabetic activity on dose dependent manner. MCEE (159±6.00 mg/dL) was1.16 times more effective comparative to OSEE (186±3.00 mg/dL), combinations of extracts shown synergistic effect (133±3.00 mg/dL) on 28th day compared with control untreated group, and combination of OSEE&MCEE (P<0.0001)  and OSAE&MCAE(P<0.001) improved insulin levels  after treatment compared to the drug solution group. OSAE and MCAE have more inhibitory effect on DPP-4 level compared to OSEE and MCEE however combinations have lesser inhibitory effect.

Article Details

How to Cite
Kuldip Kumar Savita, Raghuveer Irchhiaya, & Roopam Kushwaha. (2023). Herbal medicine as a source of DPP-4 inhibitor for the treatment of Type 2 Diabetes. Journal for ReAttach Therapy and Developmental Diversities, 6(10s(2), 2331–2341. https://doi.org/10.53555/jrtdd.v6i10s(2).2948
Issue
Vol. 6 No. 10s(2) (2023)
Section
Articles
Author Biographies

Kuldip Kumar Savita

Smt. Vidyawati College of Pharmacy, Gora Machhiya, Kanpur Road Jhansi, Uttar Pradesh

Raghuveer Irchhiaya

Institute of Pharmacy, Bundelkhand University, Jhansi, Uttar Pradesh 284128

Roopam Kushwaha

Department of Pharmacy, Smt. Vidyawati College of Pharmacy

References

Rajendra Pradeepa, &Viswanathan Mohan (2021). Epidemiology of type 2 diabetes in India. Indian Journal of Ophthalmology Volume 69 Issue 11, p2933-2938.

Nigel Unwin, Delice Gan & David Whiting (2010). The IDF Diabetes Atlas: Providing evidence, raising awareness and promoting action. Diabetes research and clinical practice 87, p 2–3.

U. Singh (2016). Prevalence of diabetes and other health related problems across India and worldwide: An overview. Journal of Applied and Natural Science 8 (1) p 500 – 505.

Shahnooshi Javad , Chndramouli R and Shenoy Ujjwala (2013).Planning and Execution of diabetes awareness and screening camp in an Educational Institution.Journal of Pharmaceutical Research Vol. 12 No.2 April-June 2013, p66-71.

Komal Shivmore & Sukhmeen Kaur Johar (2023). A Comparative Evaluation of the Effect of Metformin and Voglibose Individually and in Combination on Serum Insulin of Diabetic Patients. International Journal of Health, Environment and Research Vol. 1 No. 1, p6-10.

Mohammad Haghighatpanah, Amir Sasan Mozaffari Nejad, Maryam Haghighatpanah, Girish Thunga and Surulivelrajan Mallayasamy (2018). Factors that Correlate with Poor Glycemic Control in Type 2 Diabetes Mellitus Patients with Complications. Osong Public Health Res Perspect; 9(4), p167−174.

Alioune Camara, Naby M. Baldé, Joelle Sobngwi-Tambekou, André P. Kengne, Mansour M. Diallo, Alain P.K. Tchatchoua, Amadou Kaké, Ngamani Sylvie, Beverley Balkau, Fabrice Bonnet and Eugène Sobngwi (2015). Poor glycemic control in type 2 diabetes in the South of the Sahara: The issue of limited access to an HbA1c test. Diabetes Research and Clinical Practice, Volume 108, Issue 1 April 2015, p187-192.

Robert Beaglehole, Ruth Bonita and Liming Li (2011). UN High-Level Meeting on Non-Communicable Diseases: addressing four questions. Health Policy Volume 378, Issue 9789, July 30, P449-455.

A. Boutayeb (2010). The Burden of Communicable and Non-communicable Diseases in Developing Countries. Springer Science, Business Media LLC (USA), p532-544.

M.J. Magee & K.M. Venkat Narayan (2013). Global confluence of infectious and non-communicable diseases-The case of type 2 diabetes. Preventive Medicine, Volume57 Issue3, p149-151.

Ryan T. Demmer, Aleksandra M. Zuk, Michael Rosenbaum & Moïse Desvarieux(2013). Prevalence of Diagnosed and Undiagnosed Type 2 Diabetes Mellitus Among USAdolescents: Results From the Continuous NHANES, 1999–2010. American Journal of Epidemiology Vol. 178, No.7, p 1106–1113.

Martin C. S. Wong, Harry H. X. Wang, Mandy W. M. Kwan, Daisy D. X. Zhang,Kirin Q. L. Liu,Sky W. M. Chan, Carmen K. M. Fan, Brian C. Y. Fong, Shannon T. S. Li and Sian M. Griffiths(2014). Comparative Effectiveness of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors and Human Glucagon-Like Peptide-1 (GLP-1) Analogue as Add-On Therapies to Sulphonylurea among Diabetes Patients in the Asia-Pacific Region: A Systematic Review. PLOS ONE, March, Volume 9, Issue 3, e9096.

Martin C S Wong, Michael C M Leung, Caroline S H Tsang, S V Lo and Sian M Griffiths (2013).The rising tide of diabetes mellitus in a Chinese population: a population-based household survey on 121,895 persons. International Journal of Public Health. 2013 Apr, 58(2), p269-276.

Wenying Yang, Juming Lu, Jianping Weng (2010). Prevalence of Diabetes among Men and Women in China. The New England Journal of Medicine March, p1090-1101.

Abdulkareem J. Al-Quwaidhi, Mark S. Pearce,Eugene Sobngwi, Julia A. Critchley and Martin O’Flaherty (2014). Comparison of type 2 diabetes prevalence estimates in Saudi Arabia from a validated Markov model against the International Diabetes Federation and other modelling studies. Diabetes Research and Clinical Practice, 103, p496-503.

Kaarina Reini (2013). Diabetes Causes Substantial Losses for the Finnish Economy. National Institute for Health and welfare, http://urn:fi/URN:ISBN:978-952-245-905-3.

Nick A Roper, Rudy W Bilous, William F Kelly, Nigel C Unwin and Vincent M Connolly (2001). Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study. BMJ Volume 322 June 9.

Jais R. Bjelke, Jesper Christensen, Per F. Nielsen, Sven Branner, Anders B. Kanstrup,Nicolai Wagtmann and Hanne B. Rasmussen (2006). Dipeptidyl peptidases 8 and 9: specificity and molecular characterization compared with dipeptidyl peptidase IV. Biochemical Journal,396, p391–399.

Emi Kawakita, Daisuke Koya and Keizo Kanasaki (2021). CD26/DPP-4: Type 2 Diabetes Drug Target with Potential Influence on Cancer Biology. Cancers, 13, 2191.

Akira Saito, Joji Kitayama, Hisanaga Horie, Koji Koinuma and Rie Kawashima (2021). Dipeptidyl Peptidase (DPP)-4 Inhibitor updates impairs the Outcomes of Patients with Type 2 Diabetes Mellitus after Curative Resection for Colorectal Cancer. Cancer Research Communications, 1(2), p106-114.

Jens F Rehfeld (2018). The Origin and understanding of the Incretin concept. Frontiers in endocrinology. July Volume 9, article 387.

Laurie L. Baggio and Daniel J. Drucker (2007). Biology of Incretins: GLP-1 and GIP .Gastroenterology. Volume-132, No-6, P2131–2157.

T.D. Müller B. Finan, S.R. Bloom, D. D’Alessio,D.J. Drucker, P.R. Flatt, A. Fritsche, F. Gribble, H.J. Grill, J.F. Habener, J.J. Holst, W. Langhans, J.J. Meier, M.A. Nauck,D. Perez-Tilve, A. Pocai, F. Reimann, D.A. Sandoval, T.W. Schwartz, R.J. Seeley,K. Stemmer, M. Tang-Christensen, S.C. Woods, R.D. DiMarchi and M.H. Tschöp (2019). Glucagon-like peptide (GLP-1), Molecular Metabolism, Vol. 30, p 72-130.

Gareth E. Lim, Guan J. Huang, Nina Flora, Derek Le Roith, Christopher J. Rhodes, and Patricia L. Brubaker (2009). Insulin Regulates Glucagon-Like Peptide-1 Secretion from the Enteroendocrine L Cell. Endocrinology, February 1, 150(2), p580–591.

Daniel J. Drucker, Steven I. Sherman, Fred S. Gorelick, Richard M. Bergenstal, Robert S. Sherwin and John B. Buse (2010). Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits. Diabetes Care, Volume 33, Number 2, February p 428-433.

Diana Rohrborn, Nina Wronkowitz and Juergen Eckel(2015). DPP4 in diabetes. Frontiers in immunology, Volume6, article386.

Daniel J. Drucker (2007). Dipeptidyl Peptidase-4 Inhibition and the Treatment of Type 2 Diabetes. Diabetes Care, Volume 30, Number 6, p1335-1343.

Pathak Rolee and Bridgman Mary Barna (2010). Dipeptidyl Peptidase-4 (DPP-4) inhibitors in the Management of Diabetes, Drug Class Review, Vol. 35 No. 9,p 509-513.

Saini Kunika, Sharma Smriti and Khan Yousuf (2023). DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature, Frontiers in Molecular Biosciences, DOI,10.3389/fmolb.2023.1130625.

Ahren Bo (2019). DPP-4 Inhibition and the Path to Clinical Proof, Frontiers in Endocrinology, Volume 10, Article 376.

Jing Huang, Yuntao Jia, Shusen Sun and Long Meng (2020). Adverse event profiles of Dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system, BMC Pharmacology and Toxicology, 21:68.

FDA U.S. Food and Drug Administration, FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain, (2015) 8-28.

Kalyani Akshata , KuchyaSachin , Punekar Prashant (2021). Journal of Pharmacology and Pharmacotherapeutics, Volume 12, Issue 3, July-September, p125-130.

Teramachi H., Ohta H., Tachi T., Toyoshima M., Mizui T., Goto C. and Tsuchiya T. (2013). Pharmacoeconomic analysis of DPP-4 inhibitors, Pharmazie 68, p 909–915.

Unchalee Permsuwan, Piyameth Dilokthornsakul, Surasak Saokaew, Kednapa Thavorn and Nathorn Chaiyakunapruk (2016). Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy in elderly type 2 diabetes patients in Thailand, ClinicoEconomics and Outcomes Research ,8, p521-529.

Heera Ram, Pramod Kumar, Purohit Ashok, Kashyap Priya, Suresh Kumar, Shivani Kumar, Garima Singh, Abdulaziz A. Alqarawi, Abeer Hashem, Elsayed Fathi Abd‑Allah, Al‑Bandari Fahad Al‑Arjani and Bhim Pratap Singh(2021). Improvements in HOMA indices and pancreatic endocrinal tissues in type 2-diabetic rats by DPP-4 inhibition and antioxidant potential of an ethanol fruit extract of Withania coagulans, Nutrition &Metabolism, 18:43.p1-17.

Chhabria Srishti, Mathur Shivangi, Sebastian Vadakan, Sahoo Dipak Kumar, Mishra Pragnyashree and Paital Biswaranjan (2022). A review on phytochemical and pharmacological facets of tropical ethnomedicinal plants as reformed DPP-IV inhibitors to regulate incretin activity, Frontiers in Endocrinology, Volume 13, p1-24.

Ghasemi Asghar and Jeddi Sajad (2023). Streptozotocin as a Tool for Induction of Rat Models of Diabetes: A Practical Guide, EXCLI Journal, Volume 22, p 274-294.